NxStage Medical, Inc. (NASDAQ:NXTM) reported Q2 2017 earnings this Morning, coming in at ($0.03) per share, in-line Wall Street’s estimates of ($0.03) per Share. Revenue for the quarter came in at $92.20 million missing the streets estimates of $96.47 million
Analyst Coverage For NxStage Medical, Inc. (NASDAQ:NXTM)
These are 1 Hold Rating, 4 Buy Ratings .
The current consensus rating for NxStage Medical, Inc. (NASDAQ:NXTM) is Buy (Score: 2.80) with a consensus target price of $31.80 , a potential (37.42% upside)Recent Insider Trading for NxStage Medical, Inc. (NASDAQ:NXTM)
- On 8/3/2017 Joseph E Turk Jr, President, sold 7,000 with an average share price of $22.98 per share and the total transaction amounting to $160,860.00.
- On 7/20/2017 Matthew W Towse, SVP, sold 4,300 with an average share price of $24.16 per share and the total transaction amounting to $103,888.00.
- On 7/5/2017 Joseph E Turk Jr, President, sold 1,000 with an average share price of $25.19 per share and the total transaction amounting to $25,190.00.
- On 6/20/2017 Matthew W Towse, SVP, sold 4,300 with an average share price of $23.29 per share and the total transaction amounting to $100,147.00.
- On 6/15/2017 Winifred L Swan, SVP, sold 3,500 with an average share price of $23.14 per share and the total transaction amounting to $80,990.00.
- On 6/14/2017 Joseph E Turk Jr, President, sold 1,000 with an average share price of $23.74 per share and the total transaction amounting to $23,740.00.
Recent Trading for NxStage Medical, Inc. (NASDAQ:NXTM) Shares of NxStage Medical, Inc. closed the previous trading session at 29.70 up +6.56 28.35% with 416,858 shares trading hands.